AKBA
Akebia Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-26
Figures on this page computed 2026-11-08 13:15 UTC
Last close
0.43USD
Market data, 2026-11-05
Weekly closes, 2026-08-14 to 2026-11-05
Over that span: -51.2%
Except where said otherwise: 10-K for 2025, filed 2026-02-26
n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001517022-26-000020
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-26
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001517022-26-000020
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
-2.3%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001517022-26-000020
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
28.7%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001517022-26-000020
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
1.59Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001517022-26-000020
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Safety is the furthest below its sector's middle: 0.24 against 0.58 on the market's range.
- Growth-4.3%47 of 100, below its sector
- Returns on capital-16.4%36 of 100, above its sector
- Margins83.3%73 of 100, above its sector
- Price3.2x56 of 100, above its sector
- Safety1.5924 of 100, below its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Five bars, one line
lens 7 of 9Each against its own average
5 of 5 readExcept where said otherwise: 10-K for 2025, filed 2026-02-26
- Sales1.12x
Its own average over 10 years, 211.5M.
- Profit0.04x
Its own average over 10 years, -152.0M.
- Free cash flow-0.85x
Its own average over 10 years, -79.9M.
- Debt0.65x
Its own average over 8 years, 79.1M.
- Price0.09x
Its own average over 11 years, 5. Market data, 2026-11-05
Free cash flow is furthest from its own average, at -0.85 times.
The filed years, as a table
10Each line is 100 at 2016-12-31, the first year we hold.
| Filed year | Sales | Shares in issue |
|---|---|---|
| 2016-12-31 | 100.0 | n/a |
| 2017-12-31 | 11,806.3 | n/a |
| 2018-12-31 | 13,533.7 | n/a |
| 2019-12-31 | 21,824.2 | 100.0 |
| 2020-12-31 | 19,195.0 | 116.9 |
| 2021-12-31 | 13,788.3 | 140.2 |
| 2022-12-31 | 19,054.3 | 154.4 |
| 2023-12-31 | 12,679.0 | 158.3 |
| 2024-12-31 | 10,435.2 | 178.2 |
| 2025-12-31 | 15,387.4 | 217.2 |
How sales was got
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001517022-26-000020
- Reported in
- USD
How shares in issue was got
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001517022-26-000020
- Reported in
- USD
Figures behind the shape
Growth
-4.3%faster is higher, placed against 4,950 companies as of 2026-11-07
Five-year revenue growth rate-4.3%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
One-year change in net income92.3%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Returns on capital
-16.4%higher is higher, placed against 5,089 companies as of 2026-11-07
Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001517022-26-000020
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
Return on equity-16.4%
Net Income / Shareholders' Equity x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001517022-26-000020
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
Return on assets-1.4%
Net Income / Total Assets x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001517022-26-000020
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
Margins
83.3%wider is higher, placed against 3,412 companies as of 2026-11-07
Gross margin83.3%
Gross Profit / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001517022-26-000020
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
Operating margin9.9%
Operating Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001517022-26-000020
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
Net margin-2.3%
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001517022-26-000020
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
Free cash flow margin28.7%
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001517022-26-000020
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
Price
3.2xcheaper is higher, placed against 4,362 companies as of 2026-11-07
Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001517022-26-000020
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-26
Price to book3.2x10-Q for 2025, filed 2026-08-05
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001517022-26-000051
- Reported in
- USD
- computed
- 10-Q for 2025, filed 2026-08-05
- computed
- 10-K for 2025, filed 2026-02-26
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001517022-26-000020
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
- 10-K for 2025, filed 2026-02-26
Price to sales ratio0.4x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001517022-26-000020
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
Safety
1.59safer is higher, placed against 3,227 companies as of 2026-11-07
Debt to equity1.59
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001517022-26-000020
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-08-05
Current ratio1.5510-Q for 2025, filed 2026-08-05
Current Assets / Current Liabilities
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001517022-26-000051
- Reported in
- USD
- 10-Q for 2025, filed 2026-08-05
- 10-Q for 2025, filed 2026-08-05
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001517022-26-000020
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
Altman Z-Score-4.96
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- Computed from the 10-K for 2025, filed 2026-02-26
- Computed from the 10-K for 2025, filed 2026-02-26
- Computed from the 10-K for 2025, filed 2026-02-26
- Computed from the 10-K for 2025, filed 2026-02-26
- Computed from the 10-K for 2025, filed 2026-02-26
What it pays out
n/aWe do not hold this figure for this company, so there is nothing to place.
more, and better covered, is higher, with no cohort held
Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001517022-26-000020
- Reported in
- USD
- 10-K for 2025, filed 2026-02-26
- Computed from the 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Share a finding
A link to the finding, not to you: it carries nothing about your account.